ArticleThe Journal of infectious diseases2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.
Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cost-Effectiveness of HIV Retention and Re-engagement Interventions in High-Income Countries: A Systematic Literature Review.AIDS and behavior · 2022Pooled it
- Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review.Journal of managed care & specialty pharmacy · 2020Pooled it
- Ending the HIV Epidemic in the United States Among Men Who Have Sex With Men: A Modeling Analysis.Open forum infectious diseases · 2026Article
- Ten-Year Cost Projections for Medicare Beneficiaries 65 Years or Older With HIV.JAMA network open · 2026Article
- Development and Validation of a Predictive Screening Model for Congenital Heart Disease in High-Altitude Children.Risk management and healthcare policy · 2026Article
- Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Projected Life Expectancy Gains From Improvements in HIV Care in Black and White Men Who Have Sex With Men.JAMA network open · 2023Article
- A Growing Number of Men Who Have Sex With Men Aging With HIV (20212031): A Comparison of Two Microsimulation Models.The Journal of infectious diseases · 2023Article
- The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study.Clinical drug investigation · 2022Article
- Continuum of Care UNAIDS Fast-Track Targets Evaluation of Patients Living with Human Immunodeficiency Virus Infection.Healthcare (Basel, Switzerland) · 2021Article
- Modeling an integrated HIV prevention and care continuum to achieve the Ending the HIV Epidemic goals.AIDS (London, England) · 2020Article
- Human Immunodeficiency Virus in the State of Texas of the United States: Past Reflections, Present Shortcomings, and Future Needs of the Public Health Response.Open forum infectious diseases · 2020Review
- A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease.Journal of biomedical informatics · 2020Article
- Ending the HIV epidemic in the USA: an economic modelling study in six cities.The lancet. HIV · 2020Article
- Higher Acuity Resource Utilization With Older Age and Poorer HIV Control in Adolescents and Young Adults in the HIV Research Network.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.HIV specialist · 2020Article
- The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.AIDS (London, England) · 2020Article
- Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County.Open forum infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: The US National HIV/AIDS Strategy (NHAS) aims for 72% (90% diagnosed times 80% of those virally suppressed) viral suppression among persons with human immunodeficiency virus (HIV) by 2020. We examined the clinical and economic impact of reaching this target, in the general US population and among black men who have sex with men (MSM), the group with the highest HIV prevalence. Methods: Using a mathematical simulation, we project the 5- and 20-year clinical outcomes, costs, and incremental cost-effectiveness ratios for (1) Current Pace of detection, linkage, retention, and virologic suppression and (2) NHAS investments in expanded testing ($24-$74 per test) and adherence ($400 per person-year), calibrated to achieve 72% suppression by 2020. We examined alternative rates of testing, retention, and suppression and the efficacy and cost of adherence interventions. Results: Compared with Current Pace over 20 years, NHAS averted 280000 HIV transmissions (80000 in black MSM) and 199000 (45000) deaths and saved 2138000 (453000) years of life, while increasing costs by 23%. The incremental cost-effectiveness ratio for NHAS compared with Current Pace was $68900 per quality-adjusted life-year ($38300 for black MSM) and was most sensitive to antiretroviral therapy costs. Conclusions: Reaching NHAS targets would yield substantial clinical benefits and be cost-effective in both the general US and black MSM populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.